Post Profile






Some Breast Cancer Patients Spared Chemotherapy By New Genomic Test

Testing a breast cancer tumour for its genomic signature can help identify which patients will need adjuvant systemic therapy (additional chemotherapy) after surgery, and spare its use in those for whom it is not necessary, according to the results of a study presented to the 8th European Breast Cancer Conference (EBCC-8). Dr...
read more

share

Related Posts


Removing Breast Tumours Using Ultrasound-Guided Surgery Found To Be Preferred Method In Trial

Health : Medical News Today

The use of ultrasound-guided surgery to remove tumours from women who have palpable breast cancer is much more successful than standard surgery in excising all the cancerous tissue while sparing as much healthy tissue as possible, a...

More research urged to compare and validate genomic tests for patients with early breast cancer

Health : Medical News Today

The European Society for Medical Oncology (ESMO) has welcomed preliminary clinical trial results that suggest genomic testing could allow many patients with early breast cancer to safely avoid chemotherapy. The new trial results[1],...

Mayo Clinic Launches Whole Genome Breast Cancer Study

Health : Mayo Clinic News Blog

The Breast Cancer Genome Guided Therapy Study (BEAUTY Project) will help physicians tailor chemotherapy to breast cancer patients based on their individual genomes and the genomes of their tumors. Mayo Clinic researchers will obtain...

Use Of Genetic Information May Help Predict Likelihood Of Survival Following Chemotherapy For Breast Cancer

Health : Medical News Today

Development of a predictive test that included genomic signatures that indicated chemoresistance, chemosensitivity and endocrine sensitivity for women with newly diagnosed breast cancer identified patients with a high probability of...

Genomic Test Shows Promise As Predictor Of Chemotherapy Response, Survival For Women With Invasive Breast Cancer

Health : Medical News Today

A new genomic test combining multiple signatures a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity shows promise as a predictor of chemotherapy response and survival benefit in...

Comments


Copyright © 2016 Regator, LLC